Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,172.00
Ask: 12,174.00
Change: 108.00 (0.90%)
Spread: 2.00 (0.016%)
Open: 12,194.00
High: 12,266.00
Low: 12,054.00
Prev. Close: 12,062.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Not all mergers fall apart

Tue, 15th Sep 2020 10:33

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

NOT ALL MERGERS FALL APART (0928 GMT)

Let's face it: completing merger deals has become more challenging in this new COVID-19
world.

Take LVMH/Tiffany in luxury and Fiat Chrysler/PSA in the automotive sector. Both deals were
bigly challenged by the turmoil created by the pandemic but while LVMH resolved to call off the
deal (with political interference playing crucial part in the decision), the merger to create
the world's No. 4 carmaker is nevertheless going ahead.

But that comes with a cost, which seems investors are willing to pay, and may raise further
hopes that M&A could recover after activity collapsed in the second quarter of 2020.

To preserve cash, FCA will nearly halved its pre-merger special dividend to 2.9 billion
euros and France's PSA will in turn postpone the planned spinoff of its 46% stake in parts maker
Faurecia until after the merger's closing.

The decision might have been a tough one to take but after all that will result in a
financially stronger group, which combined with sharp increase in the synergy target explains
why their shares reacted positively at the start of trading.

It looks that investors are looking beyond any short term gains, preferring synergies
tomorrow than dividends today.

"The higher value of the industrial synergies more than offset any revision of terms," says
Equita.

PSA shares hit a 6-month high before retreating to trade down 1% on the day, while FCA
shares are up 6%.

(Danilo Masoni)

*****

STOCK PRICES RANGEBOUND UP TO END 2020 (0910 GMT)

It won’t be all about virus trajectories and macro data for the stock market as there is a
lot going on, starting with the U.S. presidential elections.

After UBS yesterday said the stock market is fragile but it was confident that investors
will turn their focus on the positives soon, JP Morgan analysts sound even more cautious.

They line up risks that equities will face and say that the STOXX 600 index will remain
rangebound by end 2020.

This is in line with our Aug 26 poll which showed investors were on average expecting the
STOXX 600, currently at 370 points, to end the year at 375 points.

On the U.S, presidential election front, the real danger is the vote ending along the lines
of the Bush versus Gore Florida recount in 2000, leading to a ”legislative paralysis for some
time,” a JP Morgan research note says.

Foreign trade is going to be an issue whoever wins as “polls suggest that the unfavourable
views of China have become firmly bipartisan,” it adds.

Technicals are not helping as positioning is far from depressed, with “short interest and
put/call ratios at lows.”

Besides, fundamentals could soften if labour market improvement stalls and if the virus
dampens the recovery; default rates might spike; geopolitical risks are in place with “Brexit,
Russia, Iran and other.”

“We do not think that any of the above risks should necessarily be seen as a clear base
case, but the potential is that some of them might be realized.”

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: BIG MOVES UNDER THE FLAT SURFACE (0715 GMT)

European shares are off to a cautious start but under the flat surface there are some big
moves.

H&M is rallying 10% after its Q3 profit beat expectations, while in the auto sector
FCA is up 7% and PSA is gaining 1% after they revised the terms of their
merged in a bid to conserve cash. The revision meant that PSA will postpone the sale of its
stake in parts maker Faurecia, which is down 8.6%.

Strong retail sales are pushing online supermarket Ocado up 4.7%.

After initial gains at the open, the STOXX 600 has now pulled back, trading down
0.10%.

(Danilo Masoni)

*****

PSA/FCA, PAYMENTS DEALS, BANKS AND VACCINE NEWS ON OUR RADAR (0639 GMT)

While rangebound trading looks set to continue in typical pre-Fed fashion -- EUROSTOXX 50
futures are just flat -- on the corporate front some dealmaking headlines could liven up the
session, along with fresh vaccine updates.

PSA and Fiat Chrysler (FCA) have revised the terms of their planned
merger to conserve cash. FCA will cut to 2.9 billion euros the cash portion of a 5.5 billion
euro special dividend, while the French group will postpone to after the merger's closing the
planned spinoff of its 46% stake in parts maker Faurecia.

In the buoyant payments industry, Klarna Bank AB has raised $650 million at a valuation of
$10.65 billion from investors led by Silver Lake, while in Italy la Repubblica
reports that Nexi and smaller rival SIA are nearing a preliminary agreement for a
merger

In banks, one day after talk of a potential tie-up between Credit Suisse and UBS
, the focus may turn to Spain. A source said Caixabank is
considering a bid for Bankia that could value it at around 4 billion euros -- a
premium of between 15% and just above 20% over Bankia's average 3-month share price.

Vaccine news does not seem so bright today with sources saying AstraZeneca's
COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a
serious side effect in Britain even as other trials of the vaccine resume.

Shares in Zurich-lised Siegfried however rose 1.9% in premarket after a contract
with BioNTech to fill and pack a potential COVID-19 vaccine, while Lonza also gained
after unveiling a collaboration deal to expand the manufacturing of Humanigen's COVID-19
therapeutic candidate Lenzilumab.

Meantime in the UK, the pandemic generated huge demand for online deliveries, sending UK
online supermarket Ocado's retail sales in the 13 weeks to Aug. up 52%.

We'll also keep an eye on Daimler after courts documents showed it will pay $2.2
billion violating U.S. clean air laws and to resolve claims from 250,000 U.S. vehicle owners.

(Danilo Masoni)

*****

MORNING CALL: A CHOPPY DAY AHEAD? (0530 GMT)

European bourses look set for another choppy session today with futures moving between flat
and slightly lower, while spreabetters' calls are pointing to marginal gains.

The main event of this week is the Fed's two-day policy meeting which could help provide
fresh direction, while the German ZEW may draw some attention later today.

The day in Asia saw Chinese stocks rise following data that showed industrial output
expanded for a fifth straight month in August, while the Nikkei pulled back.

Meantime, U.S. futures rose slightly.

Futures for the S&P 500 were up 0.3%, while EUROSTOXX 50 futures eased 0.2%

(Danilo Masoni)

*****

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.